BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Receives $20.40 Consensus Price Target from Analysts

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) has been given a consensus rating of “Moderate Buy” by the twelve ratings firms that are covering the firm, MarketBeat.com reports. Five equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. The average 12 month price target among analysts that have issued a report on the stock in the last year is $20.40.

BCRX has been the subject of a number of recent research reports. Weiss Ratings reiterated a “hold (c)” rating on shares of BioCryst Pharmaceuticals in a report on Thursday, August 27th. HC Wainwright reissued a “buy” rating and set a $32.00 price objective on shares of BioCryst Pharmaceuticals in a research note on Tuesday, June 30th. Needham & Company LLC restated a “buy” rating and set a $16.00 target price on shares of BioCryst Pharmaceuticals in a research report on Tuesday, September 8th. Royal Bank Of Canada cut shares of BioCryst Pharmaceuticals from an “outperform” rating to a “sector perform” rating and lowered their target price for the stock from $13.00 to $11.00 in a research note on Thursday, September 10th. Finally, Wall Street Zen downgraded BioCryst Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Saturday, August 29th.

BioCryst Pharmaceuticals Stock Down 0.2%

BCRX opened at $8.68 on Tuesday. The firm has a market cap of $2.22 billion, a P/E ratio of -5.79 and a beta of 0.57. The business’s fifty day simple moving average is $9.43 and its 200 day simple moving average is $9.24. BioCryst Pharmaceuticals has a 52 week low of $6.00 and a 52 week high of $11.22.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its earnings results on Wednesday, August 5th. The biotechnology company reported $0.30 earnings per share for the quarter, beating the consensus estimate of $0.15 by $0.15. The firm had revenue of $218.25 million during the quarter, compared to the consensus estimate of $183.28 million. BioCryst Pharmaceuticals had a negative net margin of 40.90% and a negative return on equity of 86.89%. The firm’s revenue for the quarter was up 33.6% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.15 EPS. As a group, equities analysts expect that BioCryst Pharmaceuticals will post -2.25 EPS for the current fiscal year.

Institutional Investors Weigh In On BioCryst Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the business. Nykredit A S acquired a new position in BioCryst Pharmaceuticals in the second quarter valued at $27,000. Larson Financial Group LLC grew its holdings in BioCryst Pharmaceuticals by 1,188.0% in the 4th quarter. Larson Financial Group LLC now owns 3,542 shares of the biotechnology company’s stock valued at $28,000 after buying an additional 3,267 shares during the period. IFP Advisors Inc grew its holdings in BioCryst Pharmaceuticals by 2,515.3% in the 2nd quarter. IFP Advisors Inc now owns 3,243 shares of the biotechnology company’s stock valued at $32,000 after buying an additional 3,119 shares during the period. Allworth Financial LP purchased a new stake in BioCryst Pharmaceuticals in the 2nd quarter valued at about $52,000. Finally, Envestnet Portfolio Solutions Inc. acquired a new position in shares of BioCryst Pharmaceuticals during the 4th quarter valued at about $81,000. Hedge funds and other institutional investors own 85.88% of the company’s stock.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes orally administered medicines for rare diseases. The company focuses on treatments that address significant unmet medical needs, using expertise in small-molecule drug discovery and development.

BioCryst’s primary commercial product is ORLADEYO (berotralstat), an oral, once-daily medication used to prevent hereditary angioedema attacks in adults and pediatric patients ages 12 and older.